戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 nd BI-RADS 3 masses stable at 12 months were eligible.
2 ico who had a sister with breast cancer were eligible.
3      Any patient undergoing bronchoscopy was eligible.
4 iabetes, or coronary artery disease were not eligible.
5 2015, with Lenstar 900 optical biometry were eligible.
6 with a child under the age of 4.5 years were eligible.
7 B hemoperfusion on mortality were considered eligible.
8 e screened for the study; 379 (81%) were not eligible.
9 e-registration healthcare professionals were eligible.
10  0 days to 23 weeks 6 days of gestation were eligible.
11 but without severe valvular dysfunction were eligible.
12 the 52 towns, of whom 27 694 were considered eligible.
13 y old, with a sister with breast cancer were eligible.
14 sires a routine eye screening examination is eligible.
15 or the treatment of patients with sepsis was eligible.
16 ge ovarian cancer who qualified for PCS were eligible.
17 to intravenous immunoglobulin treatment were eligible.
18  participated which represented 61% of those eligible.
19 uring the 20-month period, 214 patients were eligible, 182 were approached, and 32 missed.
20  to immediate vaccination (of whom 3232 were eligible, 2151 consented, and 2119 were immediately vacc
21 ed to delayed vaccination (of whom 3096 were eligible, 2539 consented, and 2041 were vaccinated 21 da
22 Of 278 ST patients, 179 (64%) were skin test eligible; 43 (24%) received testing and none were allerg
23  (e.g., tracheomalacia), among the remaining eligible 497 subjects, 51% were male, 77% white persons,
24                                              Eligible adults met DSM-IV-R binge-eating disorder crite
25 reviewed, 158 were identified as potentially eligible and 18 fulfilled eligibility criteria.
26 rom August 2013 to September 2014), 260 were eligible and 78 were enrolled (mean [SD] age, 16.5 [0.73
27 ical analysis plan included all participants eligible and correctly enrolled.
28 cluded 33 177 patients under age 65 who were eligible and due for CRC screening and managed by the pa
29  the most relevant end points for transplant-eligible and elderly fit patients with MM.
30  to be interviewed, 4% refused, and 80% were eligible and participated.
31  4, 2016, we screened 587 patients; 357 were eligible and randomly assigned to receive placebo (n=73)
32 in the state of Wisconsin would be medically eligible and willing to donate each year at the time of
33 that between 5925 and 31 097 people might be eligible and willing to donate each year.
34 tic review and meta-analysis, and identified eligible articles and candidate predictors, using PubMed
35                                              Eligible articles had to report on cohorts of patients w
36 luation after abstracts and the full text of eligible articles were screened.
37                           Of 126 potentially eligible articles, 26 were included in this study.
38 yses showed that only 8.1% of foods would be eligible based on all models (e.g., most pastas without
39 we find a steady drop in the number of grant-eligible basic-science faculty [principal investigators
40 , and 4,240 patients were deemed potentially eligible by participating GPs.
41 implantable cardioverter-defibrillator (ICD)-eligible cardiomyopathy patients.
42                                  We enrolled eligible cases declared to the National Reference Center
43                                       In all eligible cases, the diagnosis of ECD was made using clin
44       Medical records were reviewed for 1369 eligible children (712 boys [52.0%] and 657 girls [48.0%
45                         In total, 477 of 604 eligible children (79.0%) were assessed.
46 rural], and sex) in all countries to recruit eligible children aged 3-5 years from non-ethnic minorit
47                          This study included eligible children born 2002-2006 from the Norwegian Moth
48                                              Eligible children were randomized to ready-made or custo
49                                  Consecutive eligible children with peanut allergy in 3 centers were
50                                  Among 19658 eligible children, 25.8% (n = 3658) received early preve
51 eligible pregnancies and gave birth to 4,998 eligible children.
52 ildren to 20.0% (95% CI, 12.4%-30.4%) in age-eligible children.
53                      In 516 subjects (79% of eligible cohort members) who were 13 years old, serum co
54  identified 348,462 patients with one of the eligible conditions.
55                                              Eligible data on prevalence of IDU, HIV antibody, HBsAg,
56 are and Medicaid Services definitions of an "eligible death" for donation excludes patients >70 years
57              Wastewater transport from wells eligible for 2011 impact fee disbursement calculations g
58                All surgical departments were eligible for a financial incentive if they met a 5% cost
59                          Twenty patients not eligible for adalimumab were randomized to receive 12 we
60 on of patients receiving HPN were eventually eligible for an intestinal transplantation.
61      A total of 15,144 admissions (10%) were eligible for analysis once predefined exclusion criteria
62                                    481 women eligible for analysis were identified retrospectively (f
63 ropean LeukemiaNet (ELN) classification were eligible for ASCT in first remission.
64 ents with inoperable, localized HCC who were eligible for both RFA and SBRT to evaluate the cost-effe
65 lized hepatocellular carcinoma (HCC) who are eligible for both SBRT and RFA.
66 0% of patients with congestive heart failure eligible for cardiac resynchronization therapy (CRT) eit
67 ary, we provide methods to identify patients eligible for comprehensive cfDNA profiling, revealing it
68 ibroSure testing during MTX therapy and were eligible for correlation analysis.
69  local or systemic relapse of disease may be eligible for curative salvage surgery, but the benefit o
70 ion fraction</=48%) >/=4 days poststent were eligible for enrollment.
71 h problems or prescription medications, were eligible for enrollment.
72 lobectomy or bilobectomy for malignancy were eligible for enrollment.
73 ts of all ages with a diagnosis of BCNS were eligible for enrollment.
74  with men, a smaller proportion of women are eligible for EVAR, a higher proportion of women are not
75 , 2013, and Feb 10, 2015, and were therefore eligible for follow-up (1460 assigned to intervention; 1
76  $45 million toward supporting countries not eligible for Gavi funding.
77 ositivity rate or the proportion of patients eligible for HER2-targeted therapy.
78 014, resident women </=33 years had been age-eligible for HPV vaccination, with 3-dose uptake across
79                     Patients with CD who are eligible for HSCT have typically been failed by most app
80    The psychiatry unit had the most patients eligible for immediate reverse triage (72.7%; 95% CI, 59
81                                Patients were eligible for inclusion as age-matched controls if they w
82  may be at risk for cognitive impairment and eligible for inclusion in AD prevention clinical trials.
83 ning and data extraction, and 14 trials were eligible for inclusion in the review.
84 nts were recruited, and 24 736 patients were eligible for inclusion in this analysis.
85 al, Stockholm, Sweden from 2011 to 2014 were eligible for inclusion.
86 ly or confirmed diagnosis of PSP or MSA were eligible for inclusion.
87 ipts for the 2 preceding years at least were eligible for inclusion.
88 38 544 studies initially identified, 52 were eligible for inclusion.
89 f follow-up after diagnosis of diabetes were eligible for inclusion.
90 9% (n=335) of non-SHIFT-type patients became eligible for initiation of ivabradine.
91 r dysfunction and/or symptomatic disease are eligible for liver transplantation.
92 op quartile of proportion of patients dually eligible for Medicare and Medicaid) and high medical ris
93 Of the 188 articles screened, 11 (5.9%) were eligible for meta-analysis.
94 luded; providers considered 6612 (16%) to be eligible for MMR vaccine at the time of pretravel consul
95 mized controlled trial and 30% (n = 28) were eligible for only one of the 15.
96                                Patients were eligible for participation if they had: metastatic castr
97 ly modestly increase the number of hospitals eligible for penalties and would substantially increase
98 o evaluate the number of hospitals that were eligible for penalties, in that they met a volume thresh
99 ing a convenience sampling approach and were eligible for pooling given adequate ethical approval and
100 10, 1347 patients were enrolled and 676 were eligible for random allocation, 598 (88%) of whom were r
101 ginal studies (1327 eyes, 787 patients) were eligible for review.
102 s (65% men; mean age, 47.4+/-9.9 years) were eligible for speckle tracking analysis.
103 riasis (n=105), patients with hyperlipidemia eligible for statin therapy under National Cholesterol E
104 140/90 mm Hg, 76.6% (95% CI, 75.8-77.5) were eligible for statin treatment, but only 33.2% (95% CI, 3
105 nce of CAC, African American individuals not eligible for statins by USPSTF guidelines had a higher A
106 ars; interquartile range [IQR], 30-46 years) eligible for the breast cancer analysis, 5066 women (med
107 men (median age, 47 years; IQR, 40-55 years) eligible for the contralateral breast cancer analysis, 4
108                Of these, 58 individuals were eligible for the FABS-5+ study, could be located, and ag
109 men (median age, 38 years; IQR, 31-47 years) eligible for the ovarian cancer analysis, and 2213 women
110               Adults (aged >/=18 years) were eligible for the study if they had pathologically confir
111                            26 054 women were eligible for this analysis (12 807 in the intervention g
112     Of 71 patients enrolled in AURA, 53 were eligible for this analysis.
113 idelines) or small lymphocytic lymphoma were eligible for this phase 1b, dose-escalation trial.
114                                Patients were eligible for this randomised, double-blind, placebo-cont
115 quartile range, 4.2-10.2 ng/mL) were finally eligible for this retrospective analysis.
116 ts at the MD Anderson Cancer Center who were eligible for this trial but declined to participate or h
117  and assessment of early outcome in patients eligible for transcatheter aortic valve replacement.
118 s should be investigated in patients who are eligible for transthoracic access.
119  ART-naive children aged 0-12 years who were eligible for treatment to receive ART within 48 h (urgen
120  patients, and identifies candidate patients eligible for treatment.
121 te 58%); of these, 22% were in the group age-eligible for vaccination.
122                A total of 212 of 245 (86.5%) eligible hospitals responded.
123        Between Aug 4, and Dec 18, 2015, 2050 eligible households were enrolled in the prevalence surv
124                                              Eligible households were randomly assigned (1:1:1) to ei
125                            A total of 14,441 eligible ICU patients.
126                      Studies were considered eligible if they examined the effects of SCFAs, prebioti
127 m 2014 to 2016, consecutive outpatients were eligible if they had >/=1 of the following: chest/abdomi
128                                Patients were eligible if they had an ankle-brachial index (ABI) of 0.
129                                 Cohorts were eligible if they had publicly available GEP data from pa
130                                Patients were eligible if they had symptomatic thrombosis (at least 5
131                                Patients were eligible if they received combination therapy for >/=48
132                                Patients were eligible if they were at least aged 18 years, had Easter
133                                   Women were eligible if they were married, 15-40 years of age, 17-34
134                                 Studies were eligible if they were randomised controlled trials (RCTs
135                                  Based on 57 eligible individual studies including 12,137 participant
136                        Materials and Methods Eligible individuals aged 58 years (n = 1984) living in
137                                 While statin-eligible individuals by USPSTF guidelines did not have a
138 ciated with no significant change among DACA-eligible individuals in terms of self-reported overall h
139                                    Of 82,328 eligible individuals, exactly 13,000 (15.8%) completed t
140 0, 2016, we contacted 26 518 (93%) of 28 419 eligible individuals.
141                                              Eligible infants were randomly assigned (1:1) to receive
142                                        Among eligible infants, 87% and 86% received the third dose of
143 udy enrolled a consecutive sample of 318 AII-eligible inpatients from a public hospital in Seattle, W
144            Although screening is covered for eligible Medicare beneficiaries, the generalizability of
145                                Among vaccine-eligible men, the HPV vaccination coverage was 10.7% (95
146                   We finally identified 4932 eligible metastatic breast cancer patients diagnosed bet
147                                 In total, 32 eligible non-randomized studies with 4697 patients (LLR:
148 and SNAP status [current participant, income-eligible nonparticipant (income </=130% of the Federal P
149                              A total of 1210 eligible OCT scans were analyzed, resulting in 1210 data
150 up in 2011 through 2013, and 1901 of 3280 of eligible participants (72.1%) took part.
151                                              Eligible participants aged 1-18 years with newly diagnos
152       APMs have substantial advantages, with eligible participants receiving a bonus and a higher rat
153                               A total of 142 eligible participants underwent randomization at 12 Cana
154 lity occurred in 34 (4.2%) of the 812 statin-eligible participants versus five (0.4%) of the 1,384 no
155 lity occurred in 49 (6.0%) of the 812 statin-eligible participants versus nine (0.7%) of the 1,384 no
156                                              Eligible participants were aged 18-35 years in VRC19 and
157                                              Eligible participants were aged 6-11 years, weighed 25 k
158                                              Eligible participants were all women, aged 18 to 69 year
159                                              Eligible participants were healthy women aged 40-62 year
160                                              Eligible participants were HIV-uninfected men and transg
161                                              Eligible participants were insulin-naive patients with t
162                                              Eligible participants were patients with HIV who were ei
163                                              Eligible participants were randomized 1:1 to intravitrea
164                                              Eligible participants were randomly assigned to either t
165                                         1267 eligible participants were randomly assigned to the brie
166                                              Eligible participants were recruited between November 11
167          In a randomized clinical trial, 336 eligible participants who self-identified as black and 5
168                                   Among 6879 eligible participants, 1309 (19%) tested positive for in
169                                      Of 3949 eligible participants, 16% started therapy with a statin
170 lts At a median follow-up of 8.8 years among eligible participants, five (4.5%) of 110 in the control
171                          The 318 nonenrolled eligible patients (308 patients [96.9%] of whom were fol
172                             A total of 63506 eligible patients (88.6%) received CRT-D at the time of
173                                       In all eligible patients (ie, trial participants plus nonenroll
174  phosphate binders, we randomly assigned 162 eligible patients (serum phosphate =6.0 to <10.0 mg/dl a
175 ine, data were collected from 305 of the 396 eligible patients and at follow up from 326 of the 392 e
176                      Seventy-five percent of eligible patients could be evaluated with the CTC0 end p
177                                              Eligible patients for the TH3RESA trial were men and wom
178                                              Eligible patients had a streptococcal PJI that was manag
179                                              Eligible patients had adequate end-organ function, an Ea
180                                Additionally, eligible patients had at least one of the following with
181                                              Eligible patients had been enrolled at one centre in the
182                                              Eligible patients had biopsy-proven oesophageal cancer t
183                                              Eligible patients had had laboratory-confirmed EVD and h
184                                              Eligible patients had HER2-positive advanced gastric can
185                         Patients and Methods Eligible patients had locally advanced or metastatic ccR
186                                              Eligible patients had measurable disease (per RECIST ver
187                                              Eligible patients had metastatic prostate cancer and a P
188                                              Eligible patients had newly diagnosed glioblastoma confi
189 riables on 5427 continuous EEG sessions from eligible patients if they had continuous EEG for clinica
190                   There were 2,508 and 2,528 eligible patients in the 2011 and 2013 cohorts, respecti
191 s and variation in CRT-D use among guideline-eligible patients may improve patient outcomes.
192                                The number of eligible patients necessary in each randomization arm wa
193                               Three out of 6 eligible patients participated in the case series.
194                                              Eligible patients received live zoster vaccine at invest
195                                              Eligible patients received oral venetoclax, starting at
196                                 At baseline, eligible patients should show controlled attenuation par
197      Long-term outcome data from nonenrolled eligible patients support the validity of the TWENTE tri
198 e remission rates that allow more transplant-eligible patients to proceed toward consolidative high-d
199 o evaluate long-term outcomes of nonenrolled eligible patients treated with the same DESs.
200 correlation between hospitals' proportion of eligible patients treated within target time windows for
201 ariation in the use of CRT-D among guideline-eligible patients undergoing ICD placement.
202                                              Eligible patients weighed at least 15 kg, with a confirm
203                                              Eligible patients were 16-60 years, and had a first CIS
204                                              Eligible patients were adult women (aged >/=18 years) wi
205                                              Eligible patients were adults with resistant hypertensio
206                                              Eligible patients were aged 15 years or older with a dia
207                                              Eligible patients were aged 16 years and older, had cont
208                                              Eligible patients were aged 18 years or older and had hi
209                                              Eligible patients were aged 18 years or older with histo
210                                              Eligible patients were aged 18 years or older, had a dia
211                                              Eligible patients were aged 18 years or older, had a pla
212 l, multicentre, single-arm, phase 1-2 trial, eligible patients were aged 18 years or older, had histo
213  study (PACE-MDS), with long-term extension, eligible patients were aged 18 years or older, had Inter
214                                              Eligible patients were aged 18-55 years, had high-risk h
215                                              Eligible patients were aged 18-75 years, with a diagnosi
216                                              Eligible patients were aged 25-75 years, had idiopathic
217                                              Eligible patients were aged at least 18 years, with a My
218                                              Eligible patients were assigned via interactive response
219                                              Eligible patients were drug-naive or discontinued their
220                                              Eligible patients were enrolled from 58 centres across 1
221                                              Eligible patients were offered salvage radiopharmaceutic
222                                              Eligible patients were randomly assigned (1:1) by an int
223                            Patients who were eligible patients were randomly assigned (1:1) via permu
224 Between May 9, 2013, and March 20, 2015, 452 eligible patients were randomly assigned to receive daco
225                                              Eligible patients were those 16 or older with thrombocyt
226                                              Eligible patients were those aged 18 years or older with
227 itors would be very large if all potentially eligible patients were treated, which poses dilemmas for
228                                              Eligible patients were women with clinical T1 or T2 inva
229 me was the absolute number and proportion of eligible patients who completed each stage of the HCV Co
230 2 year event-free survival in all registered eligible patients who received at least 1 day of study t
231                         Patients and Methods Eligible patients with at least one prior irinotecan-con
232               Apixaban therapy for ARISTOTLE-eligible patients with atrial fibrillation provides clin
233                                              Eligible patients with coronary artery disease had to ha
234 ed training by allergists to offer BLAST for eligible patients with infectious diseases receiving non
235                                   Transplant-eligible patients with relapsed/refractory HL received 2
236 nts (ie, trial participants plus nonenrolled eligible patients), the TVF rate was only slightly highe
237                                       Of the eligible patients, 1312 underwent randomization.
238                              There were 1290 eligible patients, 259 treated for 1-3 days and 1031 tre
239                                       Of 577 eligible patients, 377 (65.3%) were enrolled and randoml
240 atients and at follow up from 326 of the 392 eligible patients, a 77% and 83% response rate respectiv
241 mong a convenience sample of 192 consecutive eligible patients, of whom 30 declined participation.
242                                              Eligible patients, stratified by baseline forced vital c
243  of 2016, including 27.3% of the potentially eligible patients.
244 priate changes to increase accessibility for eligible patients.
245 sis and staging and provide immediate ART to eligible patients.
246 ptable considering the poor prognosis of the eligible patients.
247 ical prostatectomy (RP) should be offered to eligible patients.
248 rapy boost (LDR or HDR) should be offered to eligible patients.
249                      We identified 629 study eligible-persons with at least one outcome.
250      Of these, 4,885 control women had 5,474 eligible pregnancies and gave birth to 4,998 eligible ch
251                  Databases were searched for eligible RCTs in 2 phases.
252                                  In all, 110 eligible RCTs with nonsignificant primary outcomes were
253 ur study suggests further work on converting eligible referrals to organ donation and exploring metho
254                                  Of the 1473 eligible residents, 953 consented to participate in the
255                                      Of 3736 eligible samples, 822 were from vaccinated women accordi
256              After recruitment meetings, 120 eligible schools consented and were randomly assigned to
257                                           36 eligible studies (13 cohort studies comprising 3 148 259
258                             We identified 41 eligible studies (24 from North America, 16 from Europe,
259                            We identified 106 eligible studies comprising 29 longitudinal, 49 cross-se
260 retrieved, 24 fulfilled required criteria as eligible studies for meta-analysis, involving a total of
261                       We extracted data from eligible studies for study characteristics, intervention
262                                         Five eligible studies including 4360 patients with acute ICH
263                                A total of 40 eligible studies involving 128 071 patients treated with
264                                              Eligible studies reported MRD status and progression-fre
265                                          Six eligible studies reported on a total of 810 unique patie
266                                           10 eligible studies were identified.
267                                              Eligible studies were randomized controlled trials and o
268                                              Eligible studies were RCTs that compared isolated solubl
269 ducted comprehensive literature searches for eligible studies, (3) assessed the methodological qualit
270 omes were generated by pooling patients from eligible studies.
271 nt data from 3876 participants from 13 of 16 eligible studies.
272            Individual patient data from each eligible study were requested from the authors.
273                                A total of 35 eligible subjects underwent at least a partial surgical
274                                        Of 53 eligible surrogates, 32 (60%) consented to treatment all
275                                      Methods Eligible survivors had curable breast or colorectal canc
276  2013 (postdisaster), and 82.1% of the 4,380 eligible survivors responded.
277                                      Of 1914 eligible survivors, 1503 were assessed (mean gestational
278                      To identify potentially eligible systematic reviews, we searched the Cochrane Ey
279 virus-specific T cells (VSTs) generated from eligible, third-party donors could provide broad antivir
280                               There were 132 eligible thrombectomy patients and 132 matched controls
281 rials that are largely uninformative and not eligible to be included in efficacy meta-analyses.
282 nts (age 1-20 years) with neuroblastoma were eligible to be randomly assigned if they had completed a
283                             Of 3288 patients eligible to complete 3HP, 2867 (87.2%) completed treatme
284                 A total of 303 children were eligible to participate.
285 sure would result in 76 more hospitals being eligible to receive penalties.
286 d, electronic allocation) was used to assign eligible toddlers (in a 6:1 ratio) and infants (in a 3:1
287 g 1, 2015, and Jan 29, 2016, we enrolled 345 eligible transwomen.
288                                              Eligible trials had to start randomisation on or after J
289 iew and meta-analysis, we analysed data from eligible trials that assessed the safety and efficacy of
290      We determined the publication status of eligible trials using searches of clinicaltrials.gov, Go
291      IPD were sought from investigators with eligible trials.
292 nguage restrictions up to Sept 18, 2017, for eligible trials.
293 ndomised, controlled, phase 3 AZURE trial at eligible UK sites who had stage II or III breast cancer
294 n their package (n = 747; from 1.9% of foods eligible under Modified-PAHO to 24.2% under FSANZ-NPSC).
295                      If fully implemented in eligible US adults, intensive SBP treatment could preven
296    We performed a retrospective study of all eligible veterans in the VA Capitol Health Care Network
297 able-turned-shockable rhythms were treatment-eligible, were randomized, and received their assigned d
298 population-based cohort survey study of 7303 eligible women ages 20 to 79 years with stage I and II b
299                                              Eligible women were randomly assigned (1:1) to receive e
300                             A total of 5,006 eligible women were recruited from 29 October 2013 to 7

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top